Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL

This study tests whether ibrutinib — a drug used to treat certain blood cancers — can also help patients who develop autoimmune hemolytic anemia (AIHA), a condition where the immune system mistakenly destroys red blood cells, in the context of a slow-growing blood cancer called chronic lymphocytic leukemia (CLL). **You may be eligible if...** - You are over 18 with a diagnosis of CLL, small lymphocytic lymphoma (SLL), or a related pre-cancerous condition called MBL - You have active AIHA with a hemoglobin level of 10 g/dL or lower - Your AIHA did not respond to steroids, requires high-dose steroids long-term, or came back after treatment **You may NOT be eligible if...** - You have severe heart problems (e.g., recent heart attack, uncontrolled arrhythmia) - You have severe liver or kidney problems - You are on blood thinners that cannot be safely managed - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.